Previous Close | 0.2400 |
Open | 0.2600 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 26.00 |
Expire Date | 2024-06-21 |
Day's Range | 0.1700 - 0.3600 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Key developments include a major asset sale and a focus on pharmaceutical innovation, despite a challenging financial quarter.
A young patient died due to cardiac arrest after receiving Pfizer's experimental gene therapy being tested in a mid-stage trial for a muscle-wasting disorder called Duchenne muscular dystrophy(DMD), the drugmaker told Reuters on Tuesday. "A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study," a company spokesperson told Reuters in an emailed response. The trial is testing boys 2 to three years of age with DMD, a genetic muscle wasting disorder in which most patients lack the protein dystrophin which keeps muscles intact.
A young boy died due to a cardiac arrest in a mid-stage trial that tested Pfizer's experimental gene therapy for a muscle-wasting disorder called Duchenne muscular dystrophy (DMD), the drugmaker told Reuters on Tuesday. "A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study," a company spokesperson told Reuters in an emailed response. The trial tested boys 2 years to less than 4 years of age with DMD, a genetic muscle wasting disorder in which most patients lack the protein dystrophin which keeps muscles intact.